Working to develop new treatments for osteoarthritis, researchers at Washington University School of Medicine in St. Louis have genetically engineered cartilage to deliver an anti-inflammatory drug in response to activity similar to the bending of a knee or other motions that put stress on joints.
As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines’ appropriateness for older adults with various illnesses.
Blood draws are no fun. They hurt. Veins can burst, or even roll -; like they’re trying to avoid the needle too, Oftentimes, doctors use blood samples to check for biomarkers of disease: antibodies that signal a viral or bacterial infection, such as SARS-CoV-2, the virus responsible for COVID-19, or cytokines indicative of inflammation seen […]
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Systemic sclerosis is an autoimmune disease associated with inflammation and fibrosis, or scarring, that affects organs including the skin, heart, kidney and lungs.
An international team of more than 80 collaborators led by Hospital for Special Surgery (HSS) investigators is developing new classification criteria for clinical research of antiphospholipid syndrome (APS), a life-threatening autoimmune clotting disorder.
Targeted Therapies Alliance provides new information, resources about the rheumatoid arthritis journey
Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.
A drug typically prescribed for rheumatoid arthritis may also be effective in treating a rare but potentially deadly heart complication some cancer patients experience after taking immunotherapies, according to a study published in Cancer Discovery and co-led by investigators at Vanderbilt University Medical Center.
In a new study by researchers at Universidad de Costa Rica and other institutions, a bioinformatics approach is used to determine whether Chronic COVID-19 (CC) might have a distinct immunologic signature compared to the mild to moderate (MM) or the severe/critical COVID-19.
A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center’s Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AND target tissues.